盐酸达卡他韦作用机制- Medchemexpress- MCE中国 

Product Data?SheetDaclatasvir dihydrochlorideCat. No.:CAS No.:分?式:分?量:作?靶点:作?通路:储存?式:HY-104651009119-65-6C??H??Cl?N?O?811.8HCVAnti-infectionPowderIn solvent-20°C4°C-80°C-20°C3 years2 years6 months1 monthInhibitors?Agonists?Screening Libraries溶解性数据体外实验DMSO : ≥ 56 mg/mL (68.98 mM)H2O : 50 mg/mL (61.59 mM; Need ultrasonic)* \Mass1 mg5 mg10 mgSolventConcentration制备储备液1 mM5 mM10 mM1.2318 mL0.2464 mL0.1232 mL6.1592 mL1.2318 mL0.6159 mL12.3183 mL2.4637 mL1.2318 mL请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；?旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存?式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个?内使?，-20°C 储存时，请在 1 个?内使?。体内实验请根据您的实验动物和给药?式选择适当的溶解?案。以下溶解?案都请先按照 In Vitro ?式配制澄清的储备液，再依次添加助溶剂： 为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的?作液，建议您现?现配，当天使?； 以下溶剂前显?的百分?是指该溶剂在您配制终溶液中的体积占?；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的?式助溶1. 请依序添加每种溶剂：?10% DMSO ?? 40% PEG300 ?? 5% Tween-80 ?? 45% salineSolubility: ≥ 1 mg/mL (1.23 mM); Clear solution此?案可获得 ≥ 1 mg/mL (1.23 mM，饱和度未知) 的澄清溶液。 以 1 mL ?作液为例，取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加? 50 μL Tween-80，混合均匀；然后继续加? 450 μL ?理盐?定容? 1 mL。2. 请依序添加每种溶剂：?10% DMSO ?? 90% (20% SBE-β-CD in saline)Solubility: ≥ 1 mg/mL (1.23 mM); Clear solutionPage 1 of 2 www.MedChemExpress.cn

此?案可获得 ≥ 1 mg/mL (1.23 mM，饱和度未知) 的澄清溶液。

以 1 mL ?作液为例，取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD ?理盐??溶液中，混合均匀。

3. 请依序添加每种溶剂：?10% DMSO ?? 90% corn oilSolubility: ≥ 1 mg/mL (1.23 mM); Clear solution

此?案可获得 ≥ 1 mg/mL (1.23 mM，饱和度未知) 的澄清溶液，此?案不适?于实验周期在半个?以上的实验。 以 1 mL ?作液为例，取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 900 μL ??油中，混合均匀。

BIOLOGICAL ACTIVITY

?物活性

Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) 是HCV NS5A?度选择性抑制剂，EC50为9-50 pM。

客户使?本产品发表的科研?献

????Hepatology. 2019 May;69(5):1861-1872.????EMBO Rep. 2016 Jul;17(7):1013-28.????PLoS Pathog. 2018 Sep 18;14(9):e1007284.????PLoS Pathog. 2017 May 11;13(5):e1006374.

????Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):867-876.See more customer validations on www.MedChemExpress.cnREFERENCES

[1].?Suzuki F, Sezaki H, Akuta N, Suzuki Y, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Watahiki S, Miyakawa Y, Kumada H.Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.J Clin Virol. 2012 Aug;54(4):352-4. Epub 2012 Jun 1.

[2].?Jiang H, Zeng J, Kandoussi H, Liu Y, Wang X, Bifano M, Cojocaru L, Ryan J, Arnold ME.A sensitive and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclastasvir) in human plasma and urine.J Chromatogr A. 2012 Jul 6;1245:117-21. Epub 2012 May 14.

[3].?Sun JH, O'Boyle Ii DR, Zhang Y, Wang C, Nower P, Valera L, Roberts S, Nettles RE, Fridell RA, Gao M.Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052.Hepatology. 2012 Jun;55(6):1692-9.[4].?Wang C, Jia L, Huang H, Qiu D, Valera L, Huang X, Sun JH, Nower PT, O'Boyle DR 2nd, Gao M, Fridell RA.In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.Antimicrob Agents Chemother. 2012 Mar;56(3):1588-90. Epub 2011 Dec 27.

[5].?Fridell RA et al. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother. 2010 Sep;54(9):3641-50.

McePdfHeightCaution: Product has not been fully validated for medical applications. For research use only.

Tel: 400-820-3792; 021-58955995 Fax: 021-53700325 E-mail: tech@MedChemExpress.cn

Master of Small Molecules — 您?边的抑制剂?师

Page 2 of 2 www.MedChemExpress.cn